The protein C21orf2 was reported to show cancer-associated reactivity and reacted preferentially with serum from cancer patients, including colon, stomach, breast, and prostate cancers, compared with normal human serum, with regard to serological responses41. The gene discussed is CFAP410; the disease is prostate carcinoma.